# A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma

> **NCT05645107** · PHASE3 · RECRUITING · sponsor: **Grifols Therapeutics LLC** · enrollment: 386 (estimated)

## Conditions studied

- Hypogammaglobulinemia
- Bacterial Infections
- B-cell Chronic Lymphocytic Leukemia
- Multiple Myleoma
- Non-Hodgkin Lymphoma

## Interventions

- **DRUG:** Xembify
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05645107
- **Lead sponsor:** Grifols Therapeutics LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-12-26
- **Primary completion:** 2026-05
- **Final completion:** 2026-06
- **Target enrollment:** 386 (ESTIMATED)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05645107

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05645107, "A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05645107. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*